CN101932938B - 作为标记物用于化学疗法的tle3 - Google Patents
作为标记物用于化学疗法的tle3 Download PDFInfo
- Publication number
- CN101932938B CN101932938B CN200880125991.9A CN200880125991A CN101932938B CN 101932938 B CN101932938 B CN 101932938B CN 200880125991 A CN200880125991 A CN 200880125991A CN 101932938 B CN101932938 B CN 101932938B
- Authority
- CN
- China
- Prior art keywords
- cancer
- tle3
- patient
- purposes
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99148707P | 2007-11-30 | 2007-11-30 | |
US60/991,487 | 2007-11-30 | ||
PCT/US2008/084685 WO2009073478A2 (en) | 2007-11-30 | 2008-11-25 | Tle3 as a marker for chemotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101932938A CN101932938A (zh) | 2010-12-29 |
CN101932938B true CN101932938B (zh) | 2014-08-27 |
Family
ID=40718444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880125991.9A Expired - Fee Related CN101932938B (zh) | 2007-11-30 | 2008-11-25 | 作为标记物用于化学疗法的tle3 |
Country Status (8)
Country | Link |
---|---|
US (5) | US7816084B2 (zh) |
EP (1) | EP2227693B1 (zh) |
JP (1) | JP5745273B2 (zh) |
CN (1) | CN101932938B (zh) |
CA (1) | CA2706881A1 (zh) |
GB (1) | GB2460769C (zh) |
HK (1) | HK1152563A1 (zh) |
WO (1) | WO2009073478A2 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3399450A1 (en) | 2006-05-18 | 2018-11-07 | Caris MPI, Inc. | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
US7816084B2 (en) * | 2007-11-30 | 2010-10-19 | Applied Genomics, Inc. | TLE3 as a marker for chemotherapy |
EP2347009A4 (en) * | 2008-10-14 | 2012-05-30 | Caris Mpi Inc | GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE |
CA2743211A1 (en) | 2008-11-12 | 2010-05-20 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods and systems of using exosomes for determining phenotypes |
US20110166030A1 (en) * | 2009-09-30 | 2011-07-07 | Yixin Wang | Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells |
US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
KR101976219B1 (ko) * | 2011-04-15 | 2019-05-07 | 제이 파마 가부시끼가이샤 | 유방암의 바이오마커 |
WO2013188715A2 (en) * | 2012-06-13 | 2013-12-19 | Herr John C | Compositions and methods for treating cancer |
CN102749448B (zh) * | 2012-07-27 | 2014-07-02 | 复旦大学附属中山医院 | 用于评估肺腺癌化疗效果的试剂盒 |
JP7065609B6 (ja) | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測 |
US11610644B2 (en) | 2014-10-24 | 2023-03-21 | Koninklijke Philips N.V. | Superior bioinformatics process for identifying at risk subject populations |
DK3210142T3 (da) | 2014-10-24 | 2020-11-16 | Koninklijke Philips Nv | Vurdering af tgf-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression |
WO2016118527A1 (en) | 2015-01-20 | 2016-07-28 | Nantomics, Llc | Systems and methods for response prediction to chemotherapy in high grade bladder cancer |
ES2861400T3 (es) | 2015-08-14 | 2021-10-06 | Koninklijke Philips Nv | Evaluación de la actividad de la ruta de señalización celular de NFkB usando modelos matemáticos de la expresión de genes diana |
CA3008002A1 (en) * | 2015-12-10 | 2017-06-15 | Nantomics, Llc | Integrated analysis to determine prognosis after treatment for primary breast cancer |
EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007046823A2 (en) * | 2004-11-30 | 2007-04-26 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994008037A1 (en) | 1992-09-30 | 1994-04-14 | Yale University | Human homologs of the transducin-like enhancer of split gene and methods based thereon |
WO1994007522A1 (en) * | 1992-09-30 | 1994-04-14 | Yale University | Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids |
US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
CN1054382C (zh) * | 1996-03-05 | 2000-07-12 | 核工业北京化工冶金研究院 | 用反相制备液相色谱法分离纯化紫杉醇的方法 |
WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US20030092009A1 (en) * | 2000-11-16 | 2003-05-15 | Kaia Palm | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
US20040072154A1 (en) | 2000-12-22 | 2004-04-15 | Morris David W. | Novel compositions and methods for cancer |
US7820447B2 (en) * | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
US20040029114A1 (en) * | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
ITMI20011734A1 (it) * | 2001-08-07 | 2003-02-07 | Indena Spa | Derivanti tassanici e procedimenti per la loro preparazione |
US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
US20040002067A1 (en) | 2001-12-21 | 2004-01-01 | Erlander Mark G. | Breast cancer progression signatures |
US20030216758A1 (en) * | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
WO2004048938A2 (en) * | 2002-11-26 | 2004-06-10 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
EP1581629B1 (en) | 2002-12-06 | 2015-04-01 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
US20040156884A1 (en) * | 2003-02-10 | 2004-08-12 | Brown Dale G. | Emulsion impregnated rawhide chews with antimicrobially active chlorhexidine |
EP2060918A3 (en) | 2003-04-01 | 2009-08-26 | The Johns Hopkins University | Breast endothelial cell expression patterns |
EP1668626A2 (en) * | 2003-09-22 | 2006-06-14 | Koninklijke Philips Electronics N.V. | A bi-stable display with reduced memory requirement |
GB0323225D0 (en) | 2003-10-03 | 2003-11-05 | Ncc Technology Ventures Pte Lt | Materials and methods relating to breast cancer classification |
EP1538218A1 (en) * | 2003-12-04 | 2005-06-08 | Erasmus University Medical Center Rotterdam | Method to diagnose or screen for inflammatory diseases |
CA2536096A1 (en) | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
WO2005118865A2 (en) | 2004-05-28 | 2005-12-15 | St. Jude Children's Research Hospital | Diagnosis and treatment of drug resistant leukemia |
AU2005314335C1 (en) * | 2004-12-08 | 2012-08-16 | Aventis Pharmaceuticals Inc. | Method for measuring resistance or sensitivity to docetaxel |
CN101156067A (zh) | 2005-02-16 | 2008-04-02 | 惠氏公司 | 用于白血病诊断、预后和治疗选择的方法和系统 |
WO2007086915A2 (en) | 2005-05-12 | 2007-08-02 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
CA2608092A1 (en) | 2005-05-18 | 2006-11-23 | Wyeth | Leukemia disease genes and uses thereof |
US20070172844A1 (en) * | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
JP2009532035A (ja) * | 2006-03-31 | 2009-09-10 | ブリストル−マイヤーズ スクイブ カンパニー | 微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法 |
US20090105167A1 (en) * | 2007-10-19 | 2009-04-23 | Duke University | Predicting responsiveness to cancer therapeutics |
US7816084B2 (en) * | 2007-11-30 | 2010-10-19 | Applied Genomics, Inc. | TLE3 as a marker for chemotherapy |
-
2008
- 2008-11-25 US US12/277,920 patent/US7816084B2/en not_active Expired - Fee Related
- 2008-11-25 GB GB0910374A patent/GB2460769C/en not_active Expired - Fee Related
- 2008-11-25 EP EP08855868.9A patent/EP2227693B1/en not_active Not-in-force
- 2008-11-25 WO PCT/US2008/084685 patent/WO2009073478A2/en active Application Filing
- 2008-11-25 CA CA 2706881 patent/CA2706881A1/en not_active Abandoned
- 2008-11-25 CN CN200880125991.9A patent/CN101932938B/zh not_active Expired - Fee Related
- 2008-11-25 JP JP2010536127A patent/JP5745273B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-13 US US12/578,255 patent/US7754431B2/en not_active Expired - Fee Related
-
2010
- 2010-09-24 US US12/889,630 patent/US9005900B2/en not_active Expired - Fee Related
-
2011
- 2011-06-15 HK HK11106089.6A patent/HK1152563A1/zh not_active IP Right Cessation
-
2012
- 2012-11-27 US US13/685,924 patent/US8785156B2/en not_active Expired - Fee Related
-
2015
- 2015-03-27 US US14/671,015 patent/US20150198599A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007046823A2 (en) * | 2004-11-30 | 2007-04-26 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
Non-Patent Citations (2)
Title |
---|
US2007237770A1A1 2007.10.11 |
WO2007046823A2A2 2007.04.26 |
Also Published As
Publication number | Publication date |
---|---|
US20150198599A1 (en) | 2015-07-16 |
JP2011505562A (ja) | 2011-02-24 |
WO2009073478A3 (en) | 2009-08-27 |
US9005900B2 (en) | 2015-04-14 |
US7754431B2 (en) | 2010-07-13 |
CA2706881A1 (en) | 2009-06-11 |
GB0910374D0 (en) | 2009-07-29 |
US20110015259A1 (en) | 2011-01-20 |
EP2227693B1 (en) | 2015-08-19 |
JP5745273B2 (ja) | 2015-07-08 |
WO2009073478A9 (en) | 2009-12-23 |
WO2009073478A2 (en) | 2009-06-11 |
US20100062444A1 (en) | 2010-03-11 |
EP2227693A2 (en) | 2010-09-15 |
US8785156B2 (en) | 2014-07-22 |
EP2227693A4 (en) | 2011-05-04 |
HK1152563A1 (zh) | 2012-03-02 |
US7816084B2 (en) | 2010-10-19 |
US20090155798A1 (en) | 2009-06-18 |
US20130079392A1 (en) | 2013-03-28 |
GB2460769C (en) | 2011-09-07 |
CN101932938A (zh) | 2010-12-29 |
GB2460769A (en) | 2009-12-16 |
GB2460769B (en) | 2010-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101932938B (zh) | 作为标记物用于化学疗法的tle3 | |
JP6983746B2 (ja) | 葉酸受容体1の検出用の抗体及びアッセイ | |
ES2351938T3 (es) | Reactivos y métodos para su uso en el diagnóstico, clasificación y terapia del cáncer . | |
Malempati et al. | Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group | |
KR101393144B1 (ko) | 요로상피암의 검출용 키트 및 방법 | |
CN106461681B (zh) | 用于诊断血管疾病的生物标志物及其用途 | |
AU2011281706A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
JP2013522167A (ja) | uPAR結合剤及びその使用方法 | |
Goldstein et al. | Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer | |
KR20170137848A (ko) | 폐암을 치료하는 방법 | |
US9739781B2 (en) | Anti-phospho-Akt antibodies | |
WO2000035950A9 (en) | Reagents and methods useful for detecting diseases of the breast | |
JP2015108639A (ja) | タキサン型化学療法剤用のインジケータとしてのser473でのaktリン酸化反応 | |
Kaira et al. | Evaluation of thoracic tumors with 18F‐FMT and 18F‐FDG PET‐CT: a clinicopathological study | |
US20040265932A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
WO2005017530A1 (en) | Reagents and methods for use in cancer diagnosis, classification and therapy | |
US20050048588A1 (en) | Immunogenic cancer peptides and uses thereof | |
TW202204639A (zh) | Rbm10基因的用途 | |
US6552164B1 (en) | Reagents and methods useful for detecting diseases of the breast | |
EP3690051A1 (en) | Anti-ckap4 monoclonal antibody | |
CN107589262B (zh) | 用于检测乳腺癌的试剂盒 | |
CN107589261B (zh) | 一种用于检测乳腺癌的试剂盒 | |
Kubala | The Role of NADH Dehydrogenase [Ubiquinone] 1 Alpha Subcomplex 4-Like-2 in Clear Cell Renal Cell Carcinoma | |
US20100143947A1 (en) | Reagents and methods for use in cancer diagnosis, classification and therapy | |
CN116813778A (zh) | 一种靶向中期因子mdk的d4纳米抗体及其衍生物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1152563 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: KRET DIAGNOSIS AND TREATMENT SERVICE COMPANY Free format text: FORMER OWNER: APPLIED GENOMICS, INC. Effective date: 20120907 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120907 Address after: American California Applicant after: Kret Diagnosis and Treatment Service Company Address before: American California Applicant before: Applied Genomics Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1152563 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20161125 |